Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

Published:2019-08-13 Issue:1 Volume:19 Page:
ISSN:1471-2466
Container-title:BMC Pulmonary Medicine
language:en
Short-container-title:BMC Pulm Med

Author:

Bell Scott C.,Mainz Jochen G.,MacGregor Gordon,Madge Susan,Macey Julie,Fridman Moshe,Suthoff Ellison D.,Narayanan Siva,Kinnman Nils

Funder

Vertex Pharmaceuticals Incorporated

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12890-019-0887-6.pdf

Reference30 articles.

1. Sawicki GS, Rasouliyan L, McMullen AH, Wagener JS, McColley SA, Pasta DJ, et al. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol. 2011;46:36–44.

2. Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519–31.

3. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc. 2007;4:370–7.

4. Solem CT, Vera-Llonch M, Liu S, Botteman M, Castiglione B. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes. 2016;14:63.

5. Angelis A, Kanavos P, López-Bastida J, Linertová R, Nicod E, Serrano-Aguilar P, et al. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv Res. 2015;15:428.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis;Jornal Brasileiro de Pneumologia;2023-11-16

2. Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire;Frontiers in Pharmacology;2023-10-25

3. Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaire;2023-08-02

4. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review;The European Journal of Health Economics;2022-11-05

5. Employment Status and Work Ability in Adults with Cystic Fibrosis;International Journal of Environmental Research and Public Health;2021-11-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3